A new imaging approach could change how doctors diagnose prostate cancer by helping nearly 49% of men avoid unnecessary biopsies while maintaining the ability to detect serious disease. Researchers from seven Australian hospitals tested PSMA PET scanning in men with suspicious but not obviously aggressive lesions on MRI scans, finding that the technology could reduce overdiagnosis of low-risk cancers without missing clinically significant tumors .

What Is PSMA PET Imaging and How Does It Work in Diagnosis?

PSMA PET (prostate-specific membrane antigen positron emission tomography) is an advanced imaging technique that has traditionally been used to stage advanced prostate cancer and find recurrent disease after treatment. The PRIMARY2 trial, presented at the European Association of Urology conference in March 2026, represents the first major evidence that this technology could be moved earlier in the diagnostic process .

In the study, men with MRI findings that appeared less aggressive (classified as PI-RADS 2 or PI-RADS 3 lesions) were randomly assigned to either standard care with systematic biopsy or PSMA PET scanning followed by targeted biopsy only if the scan showed concerning findings. The results demonstrated a meaningful shift in how doctors might approach diagnosis without compromising patient safety .

What Did the Trial Actually Show About Cancer Detection?

The PRIMARY2 trial produced three key findings that matter for men facing prostate cancer screening decisions. First, 49% of participants were able to avoid biopsy entirely when PSMA PET showed no concerning findings. Second, the imaging approach detected clinically significant prostate cancer at rates comparable to standard biopsy, meaning doctors weren't missing the aggressive cancers that need treatment. Third, PSMA PET reduced the diagnosis of insignificant prostate cancer, which refers to low-grade, low-volume tumors unlikely to threaten a man's life but that still require management decisions once discovered .

"We're avoiding biopsies, hopefully appropriately. We're not missing clinically significant prostate cancer, and we're avoiding the diagnosis of insignificant prostate cancer with this trial," explained Zachary Klaassen, MD, MSc, a urologist at Wellstar MCG Health.

Zachary Klaassen, MD, MSc, Wellstar MCG Health

This triple benefit addresses a central tension in prostate cancer diagnosis: doctors want to catch serious disease early, but they also want to avoid diagnosing slow-growing cancers that may never cause harm and could lead to unnecessary treatment with side effects like erectile dysfunction and urinary problems .

How to Prepare for Prostate Cancer Screening Discussions With Your Doctor

If you're a man considering prostate cancer screening or facing a potential biopsy, understanding your options can help you make informed decisions with your healthcare provider. Here are key steps to take:

• Know Your Risk Factors: Discuss with your doctor whether you have risk factors for prostate cancer, including family history, age over 50, African American ancestry, or a family history of aggressive disease.
• Ask About Imaging Options: If your doctor recommends further evaluation after an abnormal PSA test or MRI finding, ask whether PSMA PET imaging might be appropriate for your situation and whether it could reduce your need for biopsy.
• Understand the Biopsy Decision: If a biopsy is recommended, ask your doctor to explain why it's necessary, what the procedure involves, and what results would mean for your treatment options.
• Discuss Heart Health: If you're considering hormone therapy for prostate cancer, talk with your doctor about your cardiovascular risk factors, as hormone treatments can affect heart health.

The trial was funded by the Prostate Cancer Foundation and led by first author James Buteau from Australia, who was a PCF young investigator award recipient. This funding model highlights how research investment directly translates into clinical advances that change medical practice .

When Will This New Approach Be Available in US Clinics?

While the PRIMARY2 trial results are promising, experts emphasize that adoption into routine clinical practice will take time. The technology must undergo regulatory approval, insurance companies must agree to cover it, and additional validation studies will likely be needed to confirm safety over longer follow-up periods .

"Is it ready for prime time tomorrow? I think probably not. There's going to be additional validation following these patients a little bit longer," noted Phillip Koo, MD, Chief Medical Officer at the Prostate Cancer Foundation.

Phillip Koo, MD, Chief Medical Officer, Prostate Cancer Foundation

Dr. Koo emphasized that while PSMA PET imaging has already become standard for staging advanced prostate cancer and identifying patients for targeted radiotherapy treatments, moving it into the initial diagnostic phase requires careful validation. The Australian researchers plan to follow study participants for many years to ensure that the 49% of men who avoided biopsy truly did not have clinically significant cancers that were missed .

For men currently facing prostate cancer screening decisions, this research suggests that conversations with urologists about imaging options may evolve in the coming years. The goal remains the same: catch serious disease early while avoiding unnecessary procedures and overdiagnosis of cancers unlikely to cause harm. As regulatory pathways and insurance coverage develop, PSMA PET imaging may become an important tool in achieving that balance.